BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17998938)

  • 21. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
    Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
    Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
    Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
    Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
    Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR; Abe K; Karnoub AE; Der CJ
    Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
    Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
    Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
    Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
    Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H; Gelebart P; Anand M; Lai R
    Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated levels of PtdIns5P in NPM-ALK transformed cells: implication of PIKfyve.
    Coronas S; Lagarrigue F; Ramel D; Chicanne G; Delsol G; Payrastre B; Tronchère H
    Biochem Biophys Res Commun; 2008 Jul; 372(2):351-5. PubMed ID: 18501703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
    Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
    Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
    Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
    Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
    Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
    Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
    Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S
    Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
    Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
    Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
    Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
    Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The sphingolipid-rich rafts of ALK+ lymphomas downregulate the Lyn-Cbp/PAG signalosome.
    Yerly S; Ding H; Tauzin S; van Echten-Deckert G; Borisch B; Hoessli DC
    Eur J Haematol; 2010 Aug; 85(2):93-8. PubMed ID: 20561033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.